GoodRx vs Altria

Side-by-side comparison of AI visibility scores, market position, and capabilities

Altria leads in AI visibility (90 vs 31)

GoodRx

EmergingHealthcare

Prescription Savings

NASDAQ-listed (GDRX) prescription savings platform comparing prices across 70K+ pharmacies; $750M revenue with stock under pressure from Amazon Pharmacy and Cost Plus Drugs competition.

AI VisibilityBeta
Overall Score
D31
Category Rank
#1 of 1
AI Consensus
58%
Trend
stable
Per Platform
ChatGPT
25
Perplexity
31
Gemini
32

About

GoodRx is a Santa Monica-based prescription savings and healthcare price comparison platform that enables consumers to compare prices, access discount coupons, and find the lowest-cost pharmacy for their prescriptions — providing free price comparison tools across 70,000+ US pharmacies and a GoodRx Gold subscription ($9.99/month) with even lower prices on 1,000+ common medications. Listed on NASDAQ (NASDAQ: GDRX), GoodRx went public in September 2020 and generates approximately $750 million in annual revenue primarily from pharmaceutical industry fees and consumer subscription revenue.

Full profile

Altria

LeaderConsumer Goods

Enterprise

Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.

AI VisibilityBeta
Overall Score
A90
Category Rank
#83 of 290
AI Consensus
58%
Trend
stable
Per Platform
ChatGPT
84
Perplexity
97
Gemini
99

About

Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.

Full profile

AI Visibility Head-to-Head

31
Overall Score
90
#1
Category Rank
#83
58
AI Consensus
58
stable
Trend
stable
25
ChatGPT
84
31
Perplexity
97
32
Gemini
99
42
Claude
86
40
Grok
87

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.